What question did this study set out to answer?

April 1, 2026Cancers0 citationsOpen Access

Preliminary Results Regarding the Feasibility and Outcomes of MR-Linac Adaptive Stereotactic Body Radiotherapy Combined with Systemic Treatment Among Patients with Pelvic–Abdominal Recurrent or Metastatic Gynecological Malignancies: A Single-Institution Experience

Key Points

This study aims to assess the feasibility and effectiveness of MR-Linac Adaptive stereotactic body radiotherapy for recurrent pelvic–abdominal gynecological cancers.
15 patients with recurrent metastatic gynecological malignancies were treated using MR-Linac Adaptive radiotherapy.
Systemic therapies included chemotherapy, immunotherapy, and targeted therapy as adjunct treatments.
Safety, efficacy, and tolerability of the treatment were evaluated over a median follow-up of 4.67 months.
At 6 months, overall survival (OS) was 93.3%, progression-free survival (PFS) was 66.0%, and local control (LC) was 92.3%.
12-month OS was 83.8%, PFS was 37.7%, and LC was 70.5%.
The objective response rate was 73.3% for the treated lesions, with only one instance of significant toxicity.

Abstract

Objective: Inadequate radiation delivery to recurrent pelvic and abdominal tumors is frequently attributable to the dose limitations of surrounding normal structures, particularly the intestines. Radiotherapy guided by magnetic resonance imaging (MRI) significantly enhances the accuracy of soft-tissue delineation. The purposes of this study were to demonstrate the feasibility and effectiveness of MR-Linac Adaptive stereotactic body radiotherapy in patients with pelvic–abdominal recurrent or metastatic gynecological malignancies with or without systemic therapies. Methods: Patients with pelvic–abdominal recurrent or metastatic gynecological malignancies are eligible for MR-Linac Adaptive stereotactic body radiotherapy. Systemic therapies, including chemotherapy, immunotherapy, and targeted therapy, are considered acceptable treatment options. The safety, tolerability, and efficacy of MR-Linac Adaptive stereotactic body radiotherapy were assessed. Results: Between October 2019 and May 2025, 15 patients were subjected to MR-Linac Adaptive stereotactic body radiotherapy. With a median follow-up period of 4.67 months (range, 0.73–20.10 months), the 6-month overall survival (OS), progression-free survival (PFS), and local control (LC) rates were 93.3%, 66.0%, and 92.3%, respectively. The 12-month OS, PFS, and LC rates were 83.8%, 37.7%, and 70.5%, respectively. The best objective response rate (ORR = CR + PR) for the irradiated lesions was 73.3% (11/15 patients). MR-Linac Adaptive stereotactic body radiotherapy led to objective responses in 73.3% (11/15) of the patients. As of the data cutoff (28 May 2025), one patient experienced dose-limiting toxicity (an enteric fistula). Another patient developed grade 4 thrombocytopenia during treatment; it was considered chemotherapy-induced. Conclusions: These findings suggest that MR-Linac Adaptive stereotactic body radiotherapy is relatively effective and safe and can be an important treatment option for patients with pelvic–abdominal recurrent or metastatic gynecological malignancies. MR-Linac Adaptive stereotactic body radiotherapy exhibited acceptable tolerability, promising efficacy, and a favorable local control rate with regard to heavily pretreated advanced solid tumors.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper